

Model-Integrated Evidence (MIE) Industry Meeting Pilot Between FDA and Generic Drug Applicants

Liang Zhao, PhD


Director, Division of Quantitative Methods & Modeling
Office of Research and Standards, Office of Generic Drugs, CDER/FDA



SBIA

September 14th, 2023

Quantitative Methods & Modeling (QMM) for Generic Drug Development and Approval




Model-integrated evidence (MIE) refers to using model generated information such as the virtual bioequivalence (VBE) study results not just to plan a pivotal study but to serve as critical evidence

Quantitative Methods and Modeling in OGD



Oral Drug


Non-Oral Drug




Release/
Absorption/
PBPK
Models

Big
Data

Pharmaco-
metrics



- Machine learning toolsets
- Analytics for complex mixtures
- Systems pharmacology
- Risk-based models
- Business process models




PK-PD model


Population based model

What Have Been the Modeling Activities on the New Drug Side?

PDUFA VI MIDD Paired Meeting Pilot Program (2017-2022)



CDER/OCP Pilot Program Experience



* Partial year #s

Conducted as of Dec 31, 2022

Pilot Program Impact

Industrial Benefit

Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program

Gerald R. Galluppi^{1*}, Satjit Brar², Luzelena Caro³, Yuan Chen⁴, Nicolas Frey⁵, Hans Peter Grimm⁵, Deanne Jackson Rudd³, Chi-Chung Li⁶, Mindy Magee⁷, Arnab Mukherjee⁸, Lee Nagao⁹, Vivek S. Purohit¹⁰, Amit Roy¹¹, Ahmed Hamed Salem^{12,13}, Vikram Sinha^{3,†}, Ahmed A. Suleiman¹⁴, Kunal S. Taskar¹⁵, Vijay V. Upreti¹⁶, Benjamin Weber¹⁷ and Jack Cook^{18,*}

TIME

- Accelerated timelines
- Reduced sample size, faster recruitment
- Getting to right dose faster

COST

- Savings est. up to \$70M
- M/S replacing trials
- Path to potential new indications

ALIGNMENT


- Study design
- Modeling approach
- Technical feasibility
- Traction gained

CLARITY

- Direct feedback
- Technical expectations
- Additional data needs
- Engaged scrutiny

Source: Results from International Consortium for Innovation and Quality in Pharmaceutical Development survey
Clin Pharmacol Ther 2021;110(5):1172-1175

Number of pre-ANDA Interactions with Industry Proposed MIE during GDUFA II



Post FDA/CRCG Workshop Survey




- On October 27 and 28, 2022, the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics cosponsored a live virtual workshop titled “Utilizing Modeling Approaches to Support Generic Product Development.”
- More than 1,750 people registered for the workshop, and approximately 820 people attended these sessions on the day of the workshop. The workshop audience had highly diverse backgrounds, including drug product development, clinical study, and regulatory affairs
- Post workshop survey was conducted regarding using MIE for generic drug application

Survey Results



A. Did the workshop directly address issues or challenges you face related to model-integrated BE approaches to support generic product development?

How valuable did you find the content in the presentations during the workshop?

How valuable did you find the content in the panel discussions during the workshop?



How valuable would you find a communication channel with the FDA to discuss modeling approaches relevant to the use of the same model or modeling strategy across multiple submissions for complex drug products?



MIE Pilot



- **Mission:**

This new pilot program is to provide industry with meetings and opportunities for early interaction for science-driven topics using model-integrated evidence (MIE) approaches for bioequivalence (BE) establishment to facilitate generic drug development and regulatory decision making.

- **Vision:**

The pilot program allows enhanced scientific communications between generic drug developers and FDA on using a broad range of quantitative methods and modeling techniques to address generic drug development issues or questions that are either out of the scope of or cannot be sufficiently addressed by the existing pre-ANDA and ANDA scientific meetings.

Specifically, the pilot MIE meeting(s) will focus on discussing scientific and technical topics of using MIE strategies for BE establishment (e.g., feasibility, details in model building, and/or model verification and validation data) while pre-ANDA meetings will be focused on more general scientific and regulatory issue(s).

Eligibility Criteria for MIE-Pilot



- MIE-focused approaches that are innovative in nature for BE establishment and are not eligible under the existing Pre-ANDA and ANDA scientific meeting programs to address complex issues pertinent to a singular product or multiple products (e.g., common strategies for validating a computational fluid dynamics (CFD) model/platform towards predicting regional deposition of inhaled aerosols from a variety of OIDPs).
- Non-Complex Products with complex modeling approaches supporting BCS-based biowaivers and other BE study waivers that are outside current recommendations.
- Novel data analytics tools such as modeling methodology advancement or new applications of a modeling approach, e.g., equivalence analysis of complex particle size distribution (PSD), new quantitative approaches for sameness assessment, and application of novel data analytics approaches (e.g., machine learning methodology) for equivalence assessment.

Key Operational Aspects

- No more than 5 meeting grants per year
- Target launch time: October 1st, 2023
- Areas of Focus
 - Locally acting products (e.g., orally inhaled and topical dermatological products), long acting injectables, and oncology products, etc.



- Non-complex products: Novel biowaiver requests supported by mechanistic modeling

Impacts and Benefits


Industrial Benefit



Agency Benefit



- Efficiency to handle multiple products
- Reducing # of cycles for drug approval
- Eco-system with industry to develop effective BE approaches



Acknowledgment

- MIE-Pilot WG including Colleagues from
 - ORS/OGD
 - OB/OGD
 - CommS and OGDP/OGD
 - OCP/OTS
 - OPQ
- ORS and OB leaderships
 - Robert Lionberger, Lei Zhang
 - Partha Roy
- PMs
 - Maria Monroy-Osorio
 - Shivangi Goel
 - Sara Lomonaco
- DQMM modelers
- All other stakeholders